- Cetuximab C106 的研究
EGFR blockade reverts resistance to KRAS G12C inhibition in …
Co-immunoprecipitation assays using cetuximab as a capture antibody confirmed that EGFR is bound to the other HER receptors MET and FGFR suggesting hetero-dimerization processes …
EGFR Blockade Reverts Resistance to KRASG12C …
2020年8月3日 · Coimmunoprecipitation assays using cetuximab as a capture antibody confirmed that EGFR is bound to the other HER receptors, MET and FGFR, suggesting heterodimerization processes (Supplementary Fig. S2A …
Molecular Characterization of Acquired Resistance to …
2023年1月9日 · Resistant derivatives were grown in media containing cetuximab (50 μg/mL) and sotorasib (3 μmol/L). C106 cells were purchased from ECACC, and RW7213 was provided by Dr. Diego Arando (Group of Molecular …
Molecular characterization of acquired resistance to KRAS G12C ...
2022年1月12日 · Here we show that a CRC cell line that acquired resistance to sotorasib-cetuximab combination through KRAS G12C amplification became addicted to these agents …
Bcl-xL Is a Key Mediator of Apoptosis Following …
2023年1月3日 · However, addition of cetuximab to AZ’1569 only resulted in potent increases in cell death in three of seven KRAS G12C MT colorectal cancer models. Using RNA-seq, IPA, and a siRNA screening approach, we identified …
Different responses of colorectal cancer cells to …
2018年11月8日 · Cetuximab reduced the efficacy of oxaliplatin when administered before oxaliplatin but provided additive effect when administered after oxaliplatin regardless of the KRAS or BRAF mutation...
- 其他用户还问了以下问题
(PDF) Molecular Characterization of Acquired …
2022年11月10日 · C106-R and non-neoplastic cells were obtained from MissionBio’s pipeline and further used for
Cetuximab - StatPearls - NCBI Bookshelf - National Center for ...
Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor with the following FDA-approved indications: colorectal cancer, metastatic, KRAS wild-type (without mutation), and …
The EGFR-specific antibody cetuximab combined with ... - Nature
2016年5月2日 · Cetuximab is a monoclonal antibody that is effective in the treatment of metastatic colorectal cancer (mCRC). Cetuximab blocks epidermal growth factor receptor (EGFR)-ligand …
西妥昔單抗 - 维基百科，自由的百科全书
西妥昔單抗（Cetuximab），商品名爾必得舒 ® （Erbitux ® ） [1] ，是美商 英克隆公司 （ 英语 ： ImClone Systems ） 和美商百时美施贵宝的專利藥。 西妥昔單抗是一種對抗 表皮生長因子受 …